Henry Meds

Overview

Henry Meds is a cash-pay telehealth company associated with compounded hormone and weight-loss offerings, including GLP-1-class products marketed outside traditional pharmacy retail. In April 2025, Eli Lilly sued a cluster of telehealth compounders, naming Henry Meds among defendants on theories that include false advertising and related commercial claims around compounded versions of Lilly’s weight-loss drugs.

Whether any particular claim in the complaints is ultimately proven is for the courts. What matters for this desk’s public index is the industry signal: a brand-name manufacturer is no longer treating compounded GLP-1 telehealth marketing as a fringe annoyance. Docket activity creates public exhibits — complaints, exhibits lists, and trade press — that partners can cite when mapping risk across peers.

Henry Meds is therefore tracked as a litigation peer, not as a Telehealth Transparency primary field investigation. We watch how advertising claims, telehealth prescribing narratives, and corporate-practice themes are framed in the public filings.

Why we track it. Named peer in the Lilly 2025 compounded-GLP-1 litigation wave — public docket context for marketing and telehealth risk.

Tracked litigation peer — comparative public-record context only; not a primary field probe by this desk.

Public record timeline

1. Apr 2025

   Eli Lilly files multi-defendant suit wave naming Henry Meds among telehealth compounders

2. Ongoing

   Docket activity and trade coverage continue to shape how peers discuss marketing risk